<DOC>
	<DOC>NCT01217086</DOC>
	<brief_summary>This is the trial to see how our product is similar to remicade by comparing the results of blood samples when co-administered with methotrexate between 12.5 to 25 mg/week, oral or parenteral dose and folic acid in rheumatoid arthritis patients who are not receiving adequate response to methotrexate alone up to week 30.</brief_summary>
	<brief_title>Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>diagnosed with active rheumatoid arthritis at least 3 months of treatment with methotrexate have allergies to infliximab serious infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>